PET imaging of human brain gliosis using Imidazoline2 (I2) binding sites: potential biomarker for Alzheimer's disease

使用咪唑啉 2 (I2) 结合位点对人脑神经胶质增生进行 PET 成像：阿尔茨海默病的潜在生物标志物

• 批准号: G0801501/1
• 负责人: David Nutt
• 金额: $ 60.01万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2009
• 资助国家: 英国
• 起止时间: 2009 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0801501%2F1
• 关键词: PET; imaging; human; brain; gliosis

Illnesses that affect the brain such as dementia cost the NHS and the country tens of billions of pounds and are the main cause of disability in old people. In a recent report for the Alzheimer?s Society it was estimated that dementia as a whole costs the country #17.03 billion per year, or an average of #25,472 per person with dementia. Nearly 700,000 people have dementia in the UK, of which 434,000 have Alzheimer?s disease (AD). There are other brain illnesses that are less common and less costly but still very painful to the people that have them and their relatives, such as multiple sclerosis (MS) and brain tumours. One of the things these illnesses have in common is inflammation within the brain. If we were able to measure this inflammation in living humans, it would enable us better to diagnose these illnesses at an early stage when we have the best chance to cure or slow down their development. Being able to measure this inflammation will also enable us to monitor and understand these illnesses better, and any potential treatments. The purpose of this work is to develop a way of measuring this inflammation using Alzheimer?s disease as a model. The way we intend to do this is to use a very powerful technique for visualising inside humans, called positron emission tomography, or PET. PET relies on specially designed radioactive chemicals that provide a means to visualise what is happening in the brain. Therefore, we plan to develop such a radioactive chemical for a protein called the imidazoline2 binding site. This protein is found in a type of brain cell called glial. These cells are a normal part of the brain. However, in the illnesses such as Alzheimer?s where the brain is damaged and inflammation exists, there are more of these cells, especially in the inflamed areas. We already know that the amount of this protein is increased in the brains of people who have died of Alzheimer?s by studying post-mortem tissue. If we can measure a change in this protein in living patients with Alzheimer?s, it will mean we have a way of measuring this brain inflammation found in this and similar illnesses, early on giving the sufferer the best chance.

痴呆症等影响大脑的疾病给国民医疗服务体系和国家造成了数百亿英镑的损失，也是导致老年人残疾的主要原因。阿尔茨海默病协会最近的一份报告估计，整个国家每年因痴呆症造成的损失为 170.3 亿美元，即每个痴呆症患者平均损失 25,472 美元。英国有近 700,000 人患有痴呆症，其中 434,000 人患有阿尔茨海默病 (AD)。还有其他脑部疾病不太常见，成本也较低，但对患者及其亲属来说仍然非常痛苦，例如多发性硬化症 (MS) 和脑肿瘤。这些疾病的共同点之一是大脑内的炎症。如果我们能够测量活人的这种炎症，那么我们就能更好地在早期阶段诊断这些疾病，从而有最好的机会治愈或减缓它们的发展。能够测量这种炎症还将使我们能够更好地监测和了解这些疾病以及任何潜在的治疗方法。这项工作的目的是开发一种以阿尔茨海默病为模型来测量这种炎症的方法。我们打算采用一种非常强大的技术来可视化人体内部，称为正电子发射断层扫描（PET）。 PET 依靠专门设计的放射性化学物质，提供一种可视化大脑中发生的情况的方法。因此，我们计划为一种称为咪唑啉2结合位点的蛋白质开发一种放射性化学物质。这种蛋白质存在于一种称为神经胶质的脑细胞中。这些细胞是大脑的正常部分。然而，在阿尔茨海默氏症等大脑受损且存在炎症的疾病中，这些细胞的数量较多，尤其是在发炎区域。通过研究死后组织，我们已经知道，死于阿尔茨海默病的人大脑中这种蛋白质的含量有所增加。如果我们能够测量活体阿尔茨海默氏症患者体内这种蛋白质的变化，这将意味着我们有一种方法可以测量这种疾病和类似疾病中发现的大脑炎症，从而尽早为患者提供最好的机会。